Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04649866 |
| Other study ID # |
STUDY20070248 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
February 15, 2021 |
| Est. completion date |
September 1, 2023 |
Study information
| Verified date |
September 2023 |
| Source |
University of Pittsburgh |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Friedreich's ataxia is a debilitating, inherited disease cause by mutations in a protein
called frataxin (FXN). FXN is one of several proteins that controls the production of
iron-sulfur clusters, molecules that are essential for energy production in our cells as well
as repair of our genetic code embedded in DNA molecules. Friedreich's ataxia (FRDA) and
deficiency of FXN results in a nerve disease affecting coordination and a condition called
hypertrophic cardiomyopathy (HCM), marked by an abnormal thickening of the heart. Patients
with HCM can then develop pulmonary hypertension (PH), a deadly condition of the blood
vessels of the lung. While most of the research in FRDA has focused on nerves and heart
muscle, alterations in blood vessels of the heart and lung may worsen disease in FRDA. But,
the role of FXN in these blood vessels has never been defined.
Investigators pilot data suggest that Frataxin (FXN ) deficiency can control senescence and
downstream function in various types of Endothelial cells (ECs), investigators hypothesize
that Friedreich's Ataxia (FRDA) patients may demonstrate endothelial cells EC abnormalities
throughout the vasculature potentially before overt cardiomyopathy develops.
Description:
Procedure in details:
Investigators have extensive experience in the performance of forearm blood flow studies
using strain gauge plethysmography in patient volunteers. Endothelial dysfunction will be
tested according to methodologies employed in our blood flow laboratories for more than a
decade. Strain-gauge plethysmography is used to measure forearm blood flow during infusions
of acetylcholine [ACh], and sodium nitroprusside [SNP] . Intra-arterial infusions of
acetylcholine to test endothelium-dependent blood flow. Acetylcholine acts on muscarinic
receptors to increase intracellular calcium levels and activate endothelial nitic oxide (NO)
synthase. SNP is an exogenous source of NO, to assess endothelium-independent vasodilatation.
Cumulative dose response curves will be constructed over 5-minute incremental infusions.
Study doctor will proceed in the following order:
- SNP 0.8 1.6 and 3.2 mcg/min
- ACh 7.5 15 and 30 mcg/min
- Normal saline
Forearm blood flow (FBF) measurements in both arms will be made using venous occlusion
strain-gauge plethysmography prior to the initiation of any intra-arterial infusions. Blood
pressure and heart rate will be measured during the procedure through the ECG. All FBF
measurements will be expressed as mL/min per 100-1 mL forearm volume according to prior
studies and the Whitney method.1, 2 Resting baseline FBF will be measured at least 30 minutes
after venous and arterial catheter placement to ensure that blood flows in the cannulated
arms are stabilized. Study team will measure FBF during the last 2 minutes of each infusion
period. Infusions of individual vasoactive medications will occur over a 15-minute interval.
There will be a 25-minute washout between vasoactive medications. The ACh 30 mcg/min will run
for a total of 10 minutes.
Test visit:
The study will consist of one visit. Research nurse will do the lab work once subject arrive
(results will take about an hour), and if eligible study team will proceed with the research
procedure.
All subjects scheduled for the visit will report to the CTRC on the morning of testing at
8:00 AM. The subject will be placed in a quiet room with a where he will meet with the study
doctor and CRC. The study doctor will discuss with the subject the nature of the research
study, the risks of study participation, and participants' rights as a research subject. Then
will ask subject to sign consent form. After signing the consent form, the study doctor will
perform screening procedure which include the following:
- Asking questions concerning all medications prescriptions and non-prescription
medications (vitamins, herbal supplements, aspirin, etc.) that are presently taking.
Study team will be recording all this information in the subject's research record.
- Obtain a medical history and physical examination conducted by the study doctor.
- Will record height, weight, and vital signs of the subject.
- Research nurse will draw blood for laboratory testing. These tests will be a complete
blood count (a test to make sure that subject is not anemic, or have too few red blood
cells), electrolytes (tests to check the chemistry levels), glucose, and clotting tests.
These tests will be performed to evaluate the health of subjects' body during study
participation. Approximately 1 1/2 tablespoons (22 mL) of blood will be collected for
this sample.
All screening results will be reviewed by the study doctor prior to the procedure. Subject
will be provided with any abnormal screening results so that he/she can follow up with their
primary care doctor for further evaluation.
All results of these screening reports will be read by our study doctors before initiating
the study, it is possible that after taking these tests subject may not be able to take part
in this study. The total duration of this visit is approximately 3-4 hours.
Only 1 subject will be scheduled in the CTRC on any given testing day to meet appropriate
clinical staffing requirements for the study.
The CTRC nurse will place a peripheral 20-22-gauge venous catheter in the subject's
antecubital vein of the non-dominant forearm for the purpose of collecting initial blood draw
that will be used for research. After confirmation and documentation of dual arterial
perfusion of the hand by an Allen's test, Dr. Risbano (co-investigator), is a critical care
physician and qualified in this critical care procedure with 19 years' experience of doing
arterial lines, will place an 20-22 brachial artery catheter in the non-dominant arm for
infusion and blood pressure monitoring. Any non-PI physician will be personally supervised by
the PI for three cannulations before allowing independent cannulation. Prior to the brachial
artery catheter placement 1% lidocaine will be administered by injection for local
anesthesia. Brachial artery catheterization is required for the strain gauge approach to
locally administer the drugs to the forearm arterial circulation, while limiting systemic
effect. The intra-arterial catheter will be connected by a 3-way stopcock to a pressure
transducer for blood pressure measurements and to an infusion pump. Blood Flow Measurements:
Heart rate, cardiac rhythm, respirations, blood pressure, and oxygen saturation will be
continuously monitored. Forearm blood flow measurements will be performed by means of strain
gauge venous-occlusion plethysmography, using methodology employed by the PI at the Vascular
Medicine Branch of NHLBI in many other studies. plethysmography cuff pressure is
intermittent. A mercury-filled Silastic strain gauge is placed around the widest portion of
the forearm, and connected to a plethysmograph calibrated to measure the percent change in
volume. The plethysmograph is connected to a strip chart recorder for forearm blood flow
measurements following inflation of a wrist cuff to suprasystolic pressure to exclude the
hand circulation. The cuff is inflated for a duration of 8-10 seconds over a 15 second
interval. A blood pressure cuff on the upper arm is inflated to 40 mmHg for 7 seconds with a
rapid cuff inflator in order to occlude venous outflow, but not arterial inflow, into the
forearm. This causes non invisible distention of the forearm at a rate proportionate to
arterial inflow. Blood pressure will be recorded directly from the intraarterial catheter
immediately after each series of flow measurements. The use of dual arm plethysmography will
allow a direct comparison of the non-instrumented arm (as a control) with the instrumented
arm (research procedure), and serial measurements collected every 15 seconds during the
research process.
Upon completion of the research testing procedure, the study doctor will remove the venous
and arterial catheters. A doctor will personally perform the decannulation procedure. The
subject will be asked to remain in the supine position with the arm at or above heart level
and to keep the arm still during the procedure. The doctor will ensure that all infusions are
stopped and the stopcocks turned off to the patient. Any suture or tape used to secure the
line will be removed using standard precautions. The cannula will then be removed and firm
pressure held over the artery site with direct pressure of the thumb over sterile gauze for
approximately 10 minutes at which time the doctor will check for any bleeding from the
puncture site. If there is any bleeding, pressure will be held for an additional 10 minutes.
Once there is no bleeding, a pressure dressing with Coban will be placed over the site. The
subject will be instructed to remain in the supine position for an additional 10 minutes, and
to remain in the study room for a 30-minute observation period. The arm will again be
examined by the study physician prior to discharge of the subject at which time the doctor
will instruct them regarding care of their arm and provide them with an instruction sheet.
Medical Record Information: Study team will request subject's authorization to access medical
record information from their past, current and future medical record information related to
their health condition to be recorded into the Research study. This information will be
collected from Heart and Vascular Institute (HVI) records, hospital records and, if
applicable, private physician records. Since heart failure symptoms/progression may change
over time, and these changes may be important to this study result, future medical records
will be collected indefinitely. The medical record information contained within the study
database will be used for research related purposes for an indefinite time. Subjects medical
record information may be reviewed to see if they were eligible for any ongoing or future
research studies; if they were eligible, then study team may contact subjects.
Review of family history: For individuals who have a family history of FRDA, heart or lung
disease, Study team may ask some basic information about other members of the family. Study
team will not record in the Research study any identifiable information about individuals who
have not signed consent to participate in this research.
